SCHEMBL7093745

SCHEMBL7093745

CC1Oc2ccc(C(NC(=O)OC(C)(C)C)C3CCc4ccccc43)cc2NC1=S

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
RCE1 Q9Y256 1/20 0.34
IDO1 P14902 1/20 0.34
PLA2G1B P04054 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
EPHX2 P34913 1/20 0.32
DRD2 P14416 3/20 0.32
SCN9A Q15858 6/20 0.32
CALCRL Q16602 1/20 0.31
SMYD3 Q9H7B4 1/20 0.30
CTSL P07711 1/20 0.30
CTSB P07858 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094224 0.95 ALDH1A1 (0.34) KDM4EALDH1A1RCE1IDO1PLA2G1B
SCHEMBL7704930 0.87 SMYD3 (0.38) KDM4EALDH1A1RCE1IDO1SCN9A
SCHEMBL7089999 0.86 KDM4E (0.37) KDM4EALDH1A1RCE1IDO1PLA2G1B
SCHEMBL7708204 0.86 IDO1 (0.39) KDM4EALDH1A1RCE1IDO1CALCRL
SCHEMBL7704928 0.81 SMYD3 (0.35) IDO1SMYD3
SCHEMBL7705017 0.80 ALDH1A1 (0.34) KDM4EALDH1A1RCE1IDO1PLA2G1B
SCHEMBL7092653 0.78 KDM4E (0.39) KDM4EALDH1A1RCE1IDO1PLA2G1B
SCHEMBL7704943 0.76 ALDH1A1 (0.43) ALDH1A1MAPTHPGDXBP1HTT
SCHEMBL7711316 0.75 CTSS (0.38) KDM4EALDH1A1RCE1IDO1PLA2G1B
SCHEMBL6304809 0.74 MAPT (0.39) KDM4EALDH1A1RCE1PLA2G1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed